OssulinTM, a Novel Oral Insulin Product, Shows Promising Bioavailability for Advancing Diabetes Therapy

Data Presented at San Francisco Diabetes Conference

• Press Release
• Source: CM&D Pharma Limited
• On 5:00 am EST, Monday November 9, 2009

LONDON--(BUSINESS WIRE)--New data from Puredel Limited, presented at the 9^th Annual Diabetes Technology Meeting in San Francisco, CA, suggests that higher blood levels of insulin were achieved by Ossulin™ than had been previously demonstrated by other oral products. In a series of experiments covering a range of doses and models, Ossulin™ consistently delivered around 20% of the insulin dose into the bloodstream.

The authors concluded that:

Lead author and Chief Scientific Officer for Puredel, Dr. Marco Prosdocimi added:

About Puredel Limited

Puredel is focusing its research on the development of Ossulin™, which has shown promising results in preliminary studies. Puredel will also explore other target molecules which are currently injected, and whose oral administration would greatly improve patient convenience and compliance. Natreon’s R&D staff and facilities in the United States and India are working closely with Puredel to help facilitate the next stage of scientific validation prior to commercial development.

Puredel will coordinate the product development of Ossulin™ up to proof of clinical efficacy, drawing on its extensive network of scientific experts in Europe and North America.

CM&D Pharma Limited
Stephen Appelbee, CEO, +44 20 7259 8488
appelbee@cmdpharmaltd.com
www.cmdpharmaltd.com